ALS ACT awards 1MM USD grant to study RNS60’s effect in a multicenter Phase II study

The ALS Association and ALS Finding a Cure® , through ALS Accelerated Therapeutic (ALS ACT), awarded a grant in the amount of 1 million US dollars to fund an investigator-initiated, multicenter, randomized, placebo controlled Phase II study to test the effects of RNS60 in ALS patients. The study is sponsored by the Institute for Pharmacological Research Mario Negri in Milan, Italy. It targets enrollment of 142 ALS patients in 20 clinical centers in Italy and at Massachusetts General Hospital (MGH) in the U.S. The study is anticipated to start enrollment in March of 2017 and to be completed within 3 years.